Metabolytic Research

Metabolytic is developing long-acting subcutaneous delivery of peptide analogue to treat type 3c, or pancreatogenic diabetes (T3cDM). Recent estimates now indicate that accounts for 8-9% of all diabetes cases globally, or 10’s of millions of cases. There is no treatment available that specifically addresses the unique challenges of T3cDM, so we are addressing a huge unmet need.